1 / 7

Treatment

Supplemental Figure 1. Elafin Promoter Luciferase Assay in HMECs. A. pSPL94 – GFs SPL440mC/EBPβm4/5 – GFs pSPL440 – GFs pSPL94 + GFs SPL440mC/EBPβm4/5 + GFs pSPL440 + GFs. 41 118 341 26 42 100. p=0.003. Treatment. 76NF2V Quantitative RT-PCR. B. p=0.003. 81N. p=0.009. p=0.001.

colin-leonard
Download Presentation

Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Figure 1 Elafin Promoter Luciferase Assay in HMECs A pSPL94 – GFs SPL440mC/EBPβm4/5 – GFs pSPL440 – GFs pSPL94 + GFs SPL440mC/EBPβm4/5 + GFs pSPL440 + GFs 41 118 341 26 42 100 p=0.003 Treatment 76NF2V Quantitative RT-PCR B p=0.003 81N p=0.009 p=0.001 Fold Change in C/EBPβ mRNA p=0.0006 pSPL94 – GFs SPL440mC/EBPβm4/5 – GFs pSPL440 – GFs pSPL94 + GFs SPL440mC/EBPβm4/5 + GFs pSPL440 + GFs 32 85 247 43 37 100 p=0.0008 p=0.005 Control shCEBPβ1 shCEBPβ2 70N p=0.002 C 76NF2V M.W. pSPL94 – GFs SPL440mC/EBPβm4/5 – GFs pSPL440 – GFs pSPL94 + GFs SPL440mC/EBPβm4/5 + GFs pSPL440 + GFs 18 25 104 534 15 13 100 p=0.0001 Elafin p=0.0003 76N 50 Actin p=0.0002 + - + - + - GFs Control shCEBPβ1 shCEBPβ2 Percent Change

  2. Supplemental Figure 2 76NE6 76NE7 76NF2V A G0/G1 S G2 Cell Cycle Distribution Time (hours) B M.W. M.W. 76NF2V 76NE6 18 18 Elafin 50 50 Actin 76NF2V 76NE6 Relative Elafin Expression Time (hours) C Cell Cycle Distribution 81N 81NE6 81NE7 Cell Cycle Distribution + - + - + - GFs Treatment M.W. 18 D Elafin Actin 50 + - + - + - GFs 81N 81NE6 81NE7

  3. Supplemental Figure 3 A M.W. Elafin 18 50 Actin 0 6 12 24 48 0 6 12 24 48 0 6 12 24 48 hr Control shElafin 1 shElafin 2 B -GFs 48 hr M.W. 18 Elafin 50 Actin -GFs 96 hr M.W. 18 Elafin Actin Control shElafin1 + wt shElafin2 + wt shElafin1 + R1 shElafin1 + R1 M25G shElafin1 + R1 M25K shElafin2 + R2 shElafin2 + R2 M25G shElafin2 + R2 M25K 50

  4. Supplemental Figure 4 A Add Inhibitors B PBS DMSO GW311616 Sivelestat 76NE6 Percent Change in Cell Number Concentration of NE (μM) -24 0 22 24 48 72 hr Plate HMECs Remove Growth Factors Add NE MTT

  5. Supplemental Figure 5 A B 76NE6 48-hour Quantitative RT-PCR p=0.05 p=0.02 Elafin EGR1 Normalized Fold Change p=0.02 p=0.01 Control shElafin1 shElafin2

  6. Supplemental Figure 6 M.W. A 50 pERK 3.9 1.0 4.6 2.4 Total ERK 50 0 15 30 60 min B qPCR of ERK Target Genes p=0.05 EGR1 FOS Normalized Fold Change p=0.005 p=0.009 0 3 6 Time Post NE Addition (hours) C Control siRNA MEK1 siRNA DMSO U0196 pERK1/2 Total ERK1/2 0 15 30 45 0 15 30 60 0 15 30 45 15 30 45 minutes D E PBS DMSO U0126 76NE6 76NE6 siControl siMEK Percent Change in Cell Number Percent Change in Cell Number Concentration of NE (μM) Concentration of NE (μM)

  7. Supplemental Figure 7 X X 50% 50% X 100% X

More Related